$1.53
2.00% yesterday
Nasdaq, Oct 15, 10:17 pm CET
ISIN
US31189P1021
Symbol
FATE

Fate Therapeutics, Inc. Stock price

$1.53
+0.57 60.08% 1M
+0.41 36.61% 6M
-0.12 7.27% YTD
-1.52 49.84% 1Y
-19.55 92.74% 3Y
-46.57 96.82% 5Y
-3.36 68.71% 10Y
-5.09 76.89% 20Y
Nasdaq, Closing price Wed, Oct 15 2025
+0.03 2.00%
ISIN
US31189P1021
Symbol
FATE
Industry

Key metrics

Basic
Market capitalization
$176.5m
Enterprise Value
$-46.4m
Net debt
positive
Cash
$222.8m
Shares outstanding
114.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
20.8 | 26.1
EV/Sales
negative | negative
EV/FCF
0.4
P/B
0.7
Financial Health
Equity Ratio
72.3%
Return on Equity
-58.4%
ROCE
-56.1%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$8.5m | $6.8m
EBITDA
$-176.3m | $-140.4m
EBIT
$-192.4m | $-153.2m
Net Income
$-171.5m | $-134.2m
Free Cash Flow
$-118.8m
Growth (TTM | estimate)
Revenue
-31.2% | -50.5%
EBITDA
0.0% | 20.5%
EBIT
1.6% | 21.7%
Net Income
2.4% | 28.0%
Free Cash Flow
16.0%
Margin (TTM | estimate)
Gross
-
EBITDA
-2,082.0% | -2,080.6%
EBIT
-2,271.2%
Net
-2,025.1% | -1,987.7%
Free Cash Flow
-1,402.2%
More
EPS
$-1.5
FCF per Share
$-1.0
Short interest
7.9%
Employees
181
Rev per Employee
$80.0k
Show more

Is Fate Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Fate Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a Fate Therapeutics, Inc. forecast:

10x Buy
53%
9x Hold
47%

Analyst Opinions

19 Analysts have issued a Fate Therapeutics, Inc. forecast:

Buy
53%
Hold
47%

Financial data from Fate Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
8.47 8.47
31% 31%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 61 61
18% 18%
723%
- Research and Development Expense 125 125
6% 6%
1,474%
-176 -176
0% 0%
-2,082%
- Depreciation and Amortization 16 16
16% 16%
189%
EBIT (Operating Income) EBIT -192 -192
2% 2%
-2,271%
Net Profit -172 -172
2% 2%
-2,025%

In millions USD.

Don't miss a Thing! We will send you all news about Fate Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Fate Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
14 days ago
SAN DIEGO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on October 1, 2025 the Company granted to one newly-hired non-executive employ...
Neutral
GlobeNewsWire
about one month ago
SAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on September 2, 2025 the Company granted (i) non-qualified stock options to o...
Neutral
GlobeNewsWire
2 months ago
First patient treated with FT819 off-the-shelf CAR T-cell product candidate following fludarabine-free conditioning for severe lupus nephritis demonstrated durability of response with drug-free definition of remission in systemic lupus erythematosus (DORIS) at 12-month follow-up
More Fate Therapeutics, Inc. News

Company Profile

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products include immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

Head office United States
CEO Bahram Valamehr
Employees 181
Founded 2007
Website fatetherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today